OKYO Pharma, a preclinical biotech developing a lipidated chemerin analog for dry eye disease, filed on Friday with the SEC to raise up to $12 million in an initial public offering.
OKYO Pharma is developing next-generation therapies for inflammatory eye diseases and ocular pain. Its lead candidate is OK-101, a lipidated-chemerin analogue initially being developed for keratoconjunctivitis sicca, or dry eye disease (DED). The company plans to file an IND in the 2H22, followed by the commencement of a Phase 2 trial in DED patients in the 4Q22. OKYO also plans to evaluate OK-101 in patients with ocular neuropathic pain, uveitis, and allergic conjunctivitis.
The St. Peter Port, Guernsey-based company was founded in 2007 and plans to list on the Nasdaq under the symbol OKYO. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
